Last reviewed · How we verify
NCT07433452: PSILOBIOMARKER
The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.
Phase 1 trial testing Psilocybin (drug) in Healthy Participants in 50 participants. Not yet recruiting.
1 September 2028
Quick facts
| Lead sponsor | Gabriella Gobbi |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 September 2026 |
| Primary completion | 1 September 2028 |
| Estimated completion | 1 September 2029 |
Drugs / interventions tested
- Psilocybin (drug) — full drug profile →
- Placebo
Conditions studied
- Healthy Participants — all drugs for Healthy Participants →
- Placebo - Control — all drugs for Placebo - Control →
- Psilocybin — all drugs for Psilocybin →
Sponsor
Gabriella Gobbi
Who can join
Adults 21 to 65, any sex, with Healthy Participants or Placebo - Control. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, participants will received either psilocybin (the active ingredient found in certain mushrooms) or an inactive placebo (a look-alike tablet with no active drug). The psilocybin is supplied by Filament Health (Burnaby, British Columbia). After psilocybin ingestion, the body quickly converts it into psilocin, which is the form that produces the temporary psychological effects. Psilocin mainly works by interacting with serotonin receptors in the brain, especially a type called the 5-HT2A receptor. This study will be done in healthy volunteers using a single oral dose of 25 mg (one tablet by mouth), consistent with doses used in previous clinical research. The goal is to understand the biological, psychological, and high-density EEG (hd-EEG) changes that can happen after a one-time dose of psilocybin.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07433452
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Psilocybin (drug)
Trials testing the same drug.
- NCT07227909 — NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy · Phase 2 · not yet recruiting
- NCT07281352 — RCT of Psilocybin-assisted CBT for Depression · Phase 1, PHASE2 · recruiting
- NCT07183748 — Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression · Phase 2 · recruiting
- NCT07118332 — Psilocybin as a Treatment for Chronic Pain in Smokers · EARLY_PHASE1 · not yet recruiting
- NCT06969170 — Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder · Phase 2 · recruiting
Other recruiting trials for Healthy Participants
Currently open trials in the same condition.
- NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
- NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
- NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
- NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
- NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07433452 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gabriella Gobbi
- Last refreshed: 25 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07433452.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing